Alkaline phosphatase for reducing systemic inflammatory response syndrome (SIRS) in patients with Sars-CoV-2 infection and acute respiratory insufficiency (COVID 19)

Rode Kruis ziekenhuis Beverwijk0 个研究点目标入组 124 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•Patients with proved or considered Sars-CoV-2 infection admitted to the ICU with type 1 or 2 respiratory failure despite supplemental oxygen.
•Sars-CoV-2 infection based on: highly clinical suspicion on admission and/or positive PCR test on nasopharynx swab or sputum and/or a CT imaging of the chest compatible with COVID-19 + type 1 or type 2 respiratory failure despite supplemental oxygen that indicates airway support/ICU admittance and meeting any of the following criteria: .
•- SpO2 <90% or PaO2 < 60 mmHg despite FiO2 >60%
•- Clinical evidence of respiratory distress (RR > 25 breaths/minute)
•- Respiratory acidosis (pH< 7.35)

•- Inclusion in another interventional clinical trial
•- Age < 18
•- Age > 80
•- Patients who are pregnant or lactating
•- Patients expected to have fatal disease within 24 hours
•- Patients who are already on dialysis (Renal Replacement Therapy, RRT) or a decision has been made to initiate RRT within 24 hours after planned start of study drug administration
•- Patients who have advanced chronic liver disease confirmed by a Child-Pugh C
•- Patients who are having an known history of immune system that has been impaired by disease, such as patients with HIV and with a CD4 count of less than 200 cells/mm, neutropenic patients (<0.5 x 109/l) or medical treatment with immunosuppressive effects
•- Patients with active haematological malignancy

发起方

Rode Kruis ziekenhuis Beverwijk